Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Leqembi IQLIK, a once-weekly subcutaneous autoinjector for early Alzheimer's disease, is now commercially available in the U.S. — and early real-world data back it up. Patients can start treatment at home with 500 mg weekly (two 250-mg injections), skipping the clinic-based IV infusion. Small but encouraging data show most patients maintained their disease stage after switching to the at-home formulation.
Leqembi IQLIK (lecanemab-irmb), the subcutaneous autoinjector formulation of the Alzheimer's drug Leqembi, is now commercially available in the U.S. for treatment initiation in adults with early Alzheimer's disease (AD) — including those with mild cognitive impairment or mild dementia. The FDA approved the at-home starting dose in July 2026, and the drug is now accessible through the Leqembi Specialty Pharmacy Network, including CareMed and Walgreens Specialty Pharmacy.
The initiation regimen is 500 mg once weekly, delivered as two consecutive 250-mg injections in about 15 seconds each. After 18 months, patients can transition to a maintenance dose of 360 mg weekly. Patients can also switch between IV and subcutaneous routes, and standard ARIA monitoring via brain MRI remains required.
Early real-world data from the LEADER study presented at AAIC 2026 are encouraging: 85.7% of patients remained at the same disease stage after transitioning to at-home subcutaneous maintenance therapy, with no new ARIA cases or treatment discontinuations.
Key Takeaways:
Why it matters: This launch could meaningfully expand access to anti-amyloid therapy — especially for patients who live far from infusion centers or face transportation and scheduling barriers. By enabling at-home initiation, Leqembi IQLIK has the potential to reduce clinic burden and make long-term Alzheimer's treatment more sustainable for patients and caregivers alike.
